|
|
|
|
| LEADER |
04584nma a2201381 u 4500 |
| 001 |
EB002173268 |
| 003 |
EBX01000000000000001311045 |
| 005 |
00000000000000.0 |
| 007 |
cr||||||||||||||||||||| |
| 008 |
230811 ||| eng |
| 020 |
|
|
|a books978-3-0365-7574-2
|
| 020 |
|
|
|a 9783036575759
|
| 020 |
|
|
|a 9783036575742
|
| 100 |
1 |
|
|a Santulli, Gaetano
|
| 245 |
0 |
0 |
|a Translational Aspects of Cardiovascular Biology
|h Elektronische Ressource
|b From Bench to Bedside
|
| 260 |
|
|
|a Basel
|b MDPI - Multidisciplinary Digital Publishing Institute
|c 2023
|
| 300 |
|
|
|a 1 electronic resource (240 p.)
|
| 653 |
|
|
|a cardiovascular diseases
|
| 653 |
|
|
|a degenerative aortic valve stenosis
|
| 653 |
|
|
|a VEGFR
|
| 653 |
|
|
|a blood pressure
|
| 653 |
|
|
|a macrophage
|
| 653 |
|
|
|a cardiac fibrosis
|
| 653 |
|
|
|a CD38
|
| 653 |
|
|
|a ECMs
|
| 653 |
|
|
|a foam cell
|
| 653 |
|
|
|a inflammation
|
| 653 |
|
|
|a hypoxia
|
| 653 |
|
|
|a insulin resistance
|
| 653 |
|
|
|a n/a
|
| 653 |
|
|
|a vascular endothelial cells
|
| 653 |
|
|
|a laser diffraction
|
| 653 |
|
|
|a HIF-1α
|
| 653 |
|
|
|a IDH1
|
| 653 |
|
|
|a pre-clinical therapy
|
| 653 |
|
|
|a lncRNAs
|
| 653 |
|
|
|a skeletal muscle
|
| 653 |
|
|
|a microfluidics
|
| 653 |
|
|
|a CD34
|
| 653 |
|
|
|a mitochondria
|
| 653 |
|
|
|a machine perfusion
|
| 653 |
|
|
|a anemia
|
| 653 |
|
|
|a red blood cells
|
| 653 |
|
|
|a blood-brain barrier
|
| 653 |
|
|
|a ferroptosis
|
| 653 |
|
|
|a ROS
|
| 653 |
|
|
|a clinical trials
|
| 653 |
|
|
|a hypothermic oxygenated perfusion
|
| 653 |
|
|
|a NRF2
|
| 653 |
|
|
|a HUVEC
|
| 653 |
|
|
|a oxLDL
|
| 653 |
|
|
|a valvular heart disease
|
| 653 |
|
|
|a CD73
|
| 653 |
|
|
|a TGF-β
|
| 653 |
|
|
|a translational medicine
|
| 653 |
|
|
|a hypertension
|
| 653 |
|
|
|a osteoglycin
|
| 653 |
|
|
|a irisin
|
| 653 |
|
|
|a biomarkers
|
| 653 |
|
|
|a hBMECs
|
| 653 |
|
|
|a atherosclerosis
|
| 653 |
|
|
|a exosome
|
| 653 |
|
|
|a microcirculation
|
| 653 |
|
|
|a miR-4432-3p
|
| 653 |
|
|
|a HMGB-1
|
| 653 |
|
|
|a extracellular NMN metabolism
|
| 653 |
|
|
|a cancer
|
| 653 |
|
|
|a myocardial infarction
|
| 653 |
|
|
|a acute myocardial infarction
|
| 653 |
|
|
|a extracellular NAD+ metabolism
|
| 653 |
|
|
|a obesity
|
| 653 |
|
|
|a Cardiovascular medicine / bicssc
|
| 653 |
|
|
|a cardiovascular disease
|
| 653 |
|
|
|a therapeutic target
|
| 653 |
|
|
|a neuregulin
|
| 653 |
|
|
|a PCSK9
|
| 653 |
|
|
|a atherosclerotic CAD
|
| 653 |
|
|
|a diabetes
|
| 653 |
|
|
|a phosphorylcholine
|
| 653 |
|
|
|a limb ischemia
|
| 653 |
|
|
|a ERG
|
| 653 |
|
|
|a carbonic anhydrase
|
| 653 |
|
|
|a severity of CAD
|
| 653 |
|
|
|a RNA sequencing
|
| 653 |
|
|
|a endothelial function
|
| 653 |
|
|
|a vaccine
|
| 653 |
|
|
|a endothelial dysfunction
|
| 653 |
|
|
|a oxidative stress
|
| 653 |
|
|
|a inflammatory bowel disease
|
| 653 |
|
|
|a chemotherapy
|
| 653 |
|
|
|a RBP-4
|
| 653 |
|
|
|a miRNA
|
| 653 |
|
|
|a osmotic fragility test
|
| 653 |
|
|
|a endothelial cells
|
| 653 |
|
|
|a glial growth factor 2
|
| 653 |
|
|
|a liver transplantation
|
| 653 |
|
|
|a gene expression
|
| 653 |
|
|
|a cerebrovascular disease
|
| 653 |
|
|
|a periostin
|
| 653 |
|
|
|a Medicine and Nursing / bicssc
|
| 653 |
|
|
|a T2D
|
| 653 |
|
|
|a lactic acid
|
| 653 |
|
|
|a immune infiltration
|
| 653 |
|
|
|a microRNA
|
| 653 |
|
|
|a atrial fibrillation
|
| 653 |
|
|
|a nestin
|
| 653 |
|
|
|a IL-18
|
| 700 |
1 |
|
|a Santulli, Gaetano
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b DOAB
|a Directory of Open Access Books
|
| 500 |
|
|
|a Creative Commons (cc), https://creativecommons.org/licenses/by/4.0/
|
| 024 |
8 |
|
|a 10.3390/books978-3-0365-7574-2
|
| 856 |
4 |
0 |
|u https://www.mdpi.com/books/pdfview/book/7292
|7 0
|x Verlag
|3 Volltext
|
| 856 |
4 |
2 |
|u https://directory.doabooks.org/handle/20.500.12854/100829
|z DOAB: description of the publication
|
| 082 |
0 |
|
|a 610
|
| 082 |
0 |
|
|a 580
|
| 082 |
0 |
|
|a 700
|
| 520 |
|
|
|a This reprint, edited by Prof. Gaetano Santulli, MD, PhD, collects the most up-to-date peer-reviewed scientific papers dealing with cardiovascular medicine, from basic science to pre-clinical and clinical investigations, highlighting the fundamental importance of translational medicine in the challenging quest for new therapies to cure cardiovascular disease. Indeed, cardiovascular disease is the leading cause of death worldwide, and the search for novel mechanisms and therapeutics is desperately needed. Therefore, both basic and translational studies in the cardiovascular field represent a paramount strategy to identify novel therapeutic targets and improve the quality of life of patients with cardiovascular disorders.
|